+ 9.45
+ 3.01%
+ 6.79
+ 2.2%
+ 9.42
+ 2.48%

A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019

September 9, 2019 12:17 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019

This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform.

  1. ACADIA Pharmaceuticals (NASDAQ:ACAD) shares were up 62.9% after the company reported its HARMONY Phase 3 Trial met its primary endpoint. Needham maintained a Buy on the stock and raised the price target from $34 to $60.
  2. AT&T (NYSE:T) shares are up 3.1% to $37.37. Elliot Management, which holds a $3.2 billion stake in the company, sent a letter detailing his recommendations on how to make the company worth $60 per share.
  3. SINTX Technologies (NASDAQ:SINT) shares were up 16.7% to $1.61.
  4. Changeyou.com (NASDAQ:CYOU) shares were up 49.8% after the company announced it received a preliminary non-binding proposal to acquire the company from Sohu for $10 per AD.
  5. Netflix (NASDAQ:UP) shares were up 2.1% to $296. Bank of America noted the company’s download capability increased 30%.
  6. FuelCell Energy (NASDAQ:FCEL) shares were up 34.9% to $0.55. The company reported better-than-expected Q3 EPS and sales results.
  7. Cesca Therapeutics (NASDAQ:KOOL) shares were up 26.32% to $4.44 after the company entered into a global distribution agreement with ThermoGenesis to distribute its X-Series products.
  8. PaySign (NASDAQ:PAYS) shares were down 18.7% to $9.78 after the company cut its preliminary 2019 sales guidance from $38 million-$40 million to $35-$37 million. The company cited delays in onboarding of the new plasma industry programs planned for Q1 and Q2.
  9. Roku (NASDAQ:ROKU) shares were down 2% to $166.42. The company expanded its Roku TV licensing program in Europe.
  10. Cassava Sciences (NASDAQ:SAVA) shares were down 6.7% to $1.30. The company reported positive phase 2a clinical results in alzheimer's patients, data supports initiation of a phase 2b study.


Trading Ideas

Related Articles

The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings

Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week. read more

38 Stocks Moving in Thursday's Pre-Market Session

Gainers Hall of Fame Resort & Entertainment Company (NASDAQ: HOFV) rose 110% to $3.99 in pre-market trading after the company reported Q3 results and signed a media deal with Sports Illustrated Studios. read more

20 Stocks Moving In Wednesday's After-Hours Sessions

Gainers Qualcomm (NASDAQ: QCOM) shares are trading higher after the company reported better-than-expected Q4 EPS results. The company also issued Q1 EPS and sales guidance above estimates. read more

The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) read more